Ozols R F, Ostchega Y, Myers C E, Young R C
J Clin Oncol. 1985 Sep;3(9):1246-50. doi: 10.1200/JCO.1985.3.9.1246.
Nineteen previously treated refractory ovarian cancer patients, including 17 who had received standard-dose cisplatin regimens, were treated in a phase II trial with high-dose cisplatin (40 mg/m2 daily for five days with cycles administered every 28 to 35 days). Objective responses were achieved in 6/19 (32%) patients while eight patients had minor responses or stable disease. The median duration of survival from the start of salvage chemotherapy was 12 months for all patients, and 16 months for responding patients. The dose-limiting toxicity was peripheral neuropathy with 37% of patients having severe paresthesias or ataxia. These results indicate that the dose of cisplatin may be an important factor in improving survival in ovarian cancer patients.
19名先前接受过治疗的难治性卵巢癌患者，其中包括17名接受过标准剂量顺铂方案治疗的患者，在一项II期试验中接受了高剂量顺铂治疗（每日40mg/m²，共5天，每28至35天进行一个周期）。19名患者中有6名（32%）获得了客观缓解，8名患者有轻微缓解或疾病稳定。所有患者从挽救性化疗开始的中位生存期为12个月，缓解患者为16个月。剂量限制性毒性为周围神经病变，37%的患者有严重感觉异常或共济失调。这些结果表明，顺铂剂量可能是改善卵巢癌患者生存率的一个重要因素。
